Innate Pharma S.A. Files SEC Form 6-K: Key Insights & Press Release (Jan 2025)

Here are the key pieces of information extracted from the provided section of the SEC filing (Form 6-K) for Innate Pharma S.A.:

1. Filing Type and Date:

• Form: 6-K
• Date of Report: January 10, 2025

2. Company Information:

• Name: Innate Pharma S.A.
• Address: 117 Avenue de Luminy—BP 30191, 13009 Marseille, France
• Phone: +33 (0) 4 30 30 30

3. Commission File Number: 001-39084
4. Annual Report Filing:

• The company indicates it files annual reports under Form 20-F.

5. Incorporation by Reference:

• The report includes an incorporation by reference clause for Exhibit 99.1 and mentions that parts of it will be considered as part of the registration statements on Forms F-3 and S-8 (File No. 333-276164 and 333-282031 respectively).

6. Exhibit Index:

• Exhibit 99.1: Press Release dated January 10, 2025.

7. Signatures:

• The report is signed by Jonathan Dickinson, who is the Chairman of the Executive Board and Chief Executive Officer.

8. Legal Compliance:

• The filing complies with the requirements of the Securities Exchange Act of 1934.

Insights:

• This filing indicates that Innate Pharma S.A. is actively engaging with investors and regulatory bodies by submitting timely reports.
• The company is likely preparing for or responding to events relevant to its business operations, as indicated by the press release mentioned in the exhibit.
• The inclusion of the CEO's signature signifies that the information presented holds accountability at the highest operational level.